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Abstract
Background—Liquid core nanodroplets containing condensed gaseous fluorocarbons can be 
vaporized at clinically relevant acoustic energies, and have been hypothesized as an alternative 
ultrasound contrast agent instead of gas-core agents. The potential for targeted activation and 
imaging of these agents was tested with droplets formulated from liquid octafluorpropane (C3) 
and 1:1 mixtures of C3 with liquid decafluorobutane (C3C4).
Methods and Results—In eight pigs with recent myocardial infarction and variable degrees of 
reperfusion, transthoracic acoustic activation was attempted using 1.3–1.7 MHz low (0.2 
mechanical index or MI) or high MI (1.2 MI) imaging in real time (32–64 Hertz) or triggered 1:1 
at end systole during a 20% C3 or C3C4 droplet infusion. Any perfusion defects observed were 
measured and correlated with delayed enhancement magnetic resonance imaging and post mortem 
staining. No myocardial contrast was produced with any imaging setting when using C3C4 
droplets, or C3 droplets during low MI real time imaging. However, myocardial contrast was 
observed in all eight pigs with C3 droplets when using triggered high MI imaging, and in five of 
six pigs who had 1.7 MHz real time high MI imaging. Although quantitative myocardial contrast 
was lower with real time high MI imaging than 1:1 triggering, the correlation between real time 
resting defect size and infarct size was good (r=0.97, p<0.001), as was the correlation with number 
of transmural infarcted segments by delayed enhancement imaging.
Conclusions—Targeted transthoracic acoustic activation of infused intravenous C3 
nanodroplets is effective, resulting in echogenic and persistent microbubbles which provide real 
time high MI visualization of perfusion defects.
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Perfluorocarbon gases have improved the ability of microbubbles to serve as left ventricular 
diagnostic contrast agents. Their high molecular weight and reduced solubility have resulted 
in improved microbubble persistence following venous injection, permitting consistent left 
ventricular opacification and myocardial contrast (1,2). However, by the time microbubbles 
reach the systemic circulation from a venous injection, they are very susceptible to 
ultrasound induced destruction. Although this has been exploited successfully to better 
quantify myocardial perfusion (3,4), it has prevented the real time visualization of 
myocardial contrast at power outputs that could improve image quality and reduce 
attenuation. One reason for the fragility of intravenously infused microbubbles is their 
reduced size upon reaching the systemic circulation, while larger intra-arterially injected 
microbubbles are more resistant to ultrasound destruction (5).
Both octafluoropropane and decafluorobutane gases can be condensed under pressure to 
their liquid phases within lipid shells to sub-micron size droplets (6,7). These same droplets 
can be vaporized by ultrasound to reform acoustically active microbubbles at transducer-
targeted locations (8,9). The nanodroplets formulated from these low-boiling point 
perfluorocarbons require less acoustic pressure than higher boiling point perfluorocarbons, 
and purely octafluoropropane droplets have vaporized at peak negative pressures that are 
achievable with current commercially available transthoracic ultrasound systems (8,9). The 
microbubbles produced are approximately five times the size of the original droplet (7). 
Despite extensive in-vitro studies, the acoustic properties of these created microbubbles 
within the myocardial microcirculation are unknown. The purpose of this paper was to test 
whether acoustic activation of condensed low boiling point droplets was possible with 
commercially available transthoracic frequencies and clinically relevant peak negative 
pressures.
METHODS
Acoustic Droplet Preparation and Characterization
Octafluoropropane (C3) and 1:1 mixtures of octafluoropropane/decafluorobutane (C3C4) 
were formed by condensing seed microbubbles using previously established techniques 
(3,6). Briefly, in order to generate microbubbles, the headspace within stock vials of lipid 
solution was gas-exchanged with either C3 or C3C4 and subject to standard agitation 
(Vialmix, Bristol-Myers-Squibb, New York, NY). Individual microbubble vials were then 
immersed in an isopropanol bath maintained at −10°C and exposed to a gradual increase in 
external pressure using an adjustable air source until condensation was observed. The 
droplets were stable and appeared as a clear solution during infusion (Figure 1).
The sizes of the condensed droplets were polydisperse. As such, two separate sizing systems 
were required to characterize the entire range of droplet sizes. The NanoSight NS500 
(Malvern Instruments Inc., Westborough, MA) was used to capture droplet content ranging 
from 50 to 1000 nm in diameter, and the AccuSizer 780A (Particle Sizing Systems, Port 
Richey, FL) was used to capture droplet content ranging from 500 to 50,000 nm in diameter. 
According to the NanoSight system, the average distribution (3 separate vials) of C3 
droplets had a mode size of 109.1 +/− 6.8 nm and a total concentration of 2.8 × 1011 +/− 1.3 
× 1011 particles/ml, whereas C3C4 droplets had a mode size of 125.9 +/− 3.6 nm and a total 
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concentration of 1.6 × 1011 +/− 8.8 × 1010. The differences in size and concentration 
between C3 and C3C4 droplets are expected based on ideal gas laws and the concentration 
of seed microbubbles (8). According to the AccuSizer, the average distribution (3 separate 
vials) of C3 droplets had a mode size of 623.3 +/− 37.9 nm and a total concentration of 2.6 × 
108 +/− 3.3 × 107 particles/ml, whereas C3C4 droplets had a mode size of 610.0 +/− 10.0 
nm and a total concentration of 3.2 × 108 +/− 3.5 × 107. It is important to note that although 
the concentration of larger droplet content reported by the AccuSizer is three orders of 
magnitude larger than that reported by the NanoSight, it is likely this larger droplet content 
is primarily responsible for contrast enhancement.
Animal Studies
All studies performed were approved by the Institutional Animal Care and Use Committee 
at the University of Nebraska Medical Center. Eight pigs (mean weight 64 ± 6 kg) who were 
48 hours post an acute ST segment elevation myocardial infarction were studied. One 
additional pig without infarction was utilized to demonstrate the effect of mechanical index 
on activation threshold in real time and the wash out of activated droplets from the 
myocardium and left ventricular cavity. The infarction was created using an established 
protocol (10,11) that involves balloon injury of the mid left anterior descending artery 
followed by a 50 day 15% lard diet. At 50 days, the left anterior descending was balloon-
injured again in the same location, following which the balloon was reinflated slightly 
proximal to the injury site to create stasis, and small 0.2–0.3 milliliter aliquots of 
thrombosing venous blood were re-injected through the balloon catheter until a sustained 
(20 minute) angiographic occlusion was achieved. Pigs were then treated with intermittent 
high mechanical index impulses (1.0 mechanical index) from a modified low frequency 
diagnostic and therapeutic transducer (900 kHz GE Vivid E9; GE Global Research) during a 
30 minute intravenous microbubble infusion (3% Definity). All pigs received 300 mg of 
aspirin and 600 milligrams of clopidogrel via a nasogastric tube combined with a heparin 
infusion for sixty minutes. Using this protocol epicardial recanalization occurred in five of 
the eight pigs by 90 minutes into therapy. Following the myocardial infarction and 
ultrasound treatment, all pigs were allowed to recover and placed back on a regular diet for 
two days.
At 48 hours post infarction, the pigs underwent cardiac magnetic resonance exams 
(described below) to define infarct size. Following this, pigs underwent 20% intravenous 
infusions (diluted in normal saline) of C3 or 20% infusion of the 1:1 ratio of C3C4 droplets. 
Imaging was initiated at one minute after the infusion was started. Each infusion was 
separated from the other by five-seven minutes to allow clearance of the previous droplets 
from the system, which was verified by ultrasound imaging. Before and during all infusions, 
arterial blood pressure, heart rate, and oxygen saturation monitoring were recorded.
Ultrasound Activation Protocols
Using a Philips S5-1 transducer (Philips Healthcare), a triggered harmonic high mechanical 
index (MI) at 1.3 MHz (1.1 MI) was tested using mid and distal short axis imaging of the 
left ventricle. At the 1.3 MHz harmonic setting, the images were triggered to end systole at 
either one frame every one cardiac cycle or every four cardiac cycles. We also tested two 
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real time settings: A 20 Hz frame rate low MI (0.2–0.25) setting (Power Modulation) 
traditionally used for microbubble imaging at 1.7 MHz, and a high MI (1.2 MI) real time 
setting of 1.7 MHz harmonic imaging. The purpose of the high MI real time setting was to 
determine if droplets within the microcirculation could be activated and still visualized 
without destruction. To further evaluate this in three of the pigs, myocardial contrast 
enhancement with the 1.7 MHz real time setting was compared with the 1:1 triggered setting 
at the same MI during the continuous infusion to determine if there was evidence of 
differences in myocardial signal enhancement due to destruction. The wash out of the 
myocardial and left ventricular cavity contrast following infusion termination was also 
analyzed using Q lab measurements of digital intensity versus time.
All three settings (triggered 1.3/2.6 MHz harmonic, low MI 1.7 MHz power modulation 
imaging, and real time 1.7 MHz high MI imaging) were tested for both intravenous C3 and 
C3C4 droplet infusions. Prior to sacrifice, the pigs had a balloon catheter advanced under 
fluoroscopy into the same location as the original LAD occlusion and inflated to re-occlude 
the infarct vessel (if it was recanalized). No balloon was inserted if the vessel remained 
occluded at the original injury site. Following this, a total of 65 ml of 3% Evans Blue (40 ml 
in the left main, 25 ml in the right coronary) was then injected through coronary catheters 
placed in the right and left main coronary arteries to define risk area. The pigs were 
subsequent sacrificed and post mortem triphenyl tetrazolium chloride (TTC) staining of 
infarct size and Evans Blue (EB) measurements of risk area were determined using 
planimetry.
Magnetic resonance imaging (MRI), Risk Area, and Post Mortem TTC Staining
MRI scans were also performed at 48 hours following infarction just prior to droplet 
infusion studies using a 1.5 Tesla Magnet (Philips Achieva XL: Best, The Netherlands). 
Cine images using steady state free precession were obtained in serial short axis views (slice 
thickness 8 cm, slice gap 2 cm, 45 msec temporal resolution, flip angle 60 degrees; TR 3 
msec; TE 1.5 msec) to quantify left ventricular ejection fraction using the Philips View 
Forum workstation. Following this, 0.15 mmol/kilogram of 0.2 mmol/kg dimeglumine 
gadopentatate (Magnevist: Bayer) was injected. At 10 minutes post injection, all short axis 
views were examined using an inversion recovery turbo fast field echo/gradient recall ECG-
triggered, segmented image collection for detection of extent of necrosis. Using a 16 
segment model, segments exhibiting transmural (>50% thickness at end diastole) 
hyperenhancement, and segments exhibiting any microvascular obstruction (persistent 
unenhanced portions within the hyperenhanced segments) were recorded using established 
criteria (12). All image interpretation and quantification was performed by an experienced 
level III trained cardiologist (SS) who was blinded to echocardiographic and post mortem 
staining results.
Statistical Comparisons
Since the presence or absence of myocardial contrast at high and low mechanical indices 
were obvious and consistent, comparisons of the presence or absence of myocardial contrast 
using the different imaging techniques utilized to activate the intravenously infused C3 
versus C3C4 droplets were descriptive and not determined with contingency tables. When 
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comparing myocardial contrast intensity between real time and triggered frame rates in the 
different animals (n=18 comparisons in three animals), a covariance structure which treats 
random variation due to the three pigs was performed, which then treats the paired data with 
a 2×2 unstructured co-variance matrix. The average size of any visualized perfusion defect 
(at rest and during repeat LAD occlusion) with any of the imaging techniques was 
planimetered off line, and compared with post mortem EB and TTC staining using a 
Spearman correlation with an exact p value to summarize the association. The planimetered 
size of any defect was also compared with the number of segments (using a 16 segment 
model) exhibiting transmural (>50% transmural thickness) delayed enhancement on post 
gadolinium magnetic resonance imaging using a Spearman correlation coefficient. Statistical 
analyses were generated with SAS/STAT software, Version 9.4 (© 2002 – 2012 SAS 
Institute Inc.)
RESULTS
Activation Thresholds for Transthoracic Real Time Imaging of Myocardial Contrast 
Enhancement
Figure 2 and Video 1 demonstrate the effect of mechanical index on the presence of 
myocardial contrast enhancement achieved with a continuous intravenous C3 infusion. Note 
that at a specific mechanical index (0.8) we begin to see myocardial and left ventricular 
cavity contrast which eventually encompasses the entire short axis at the 1.2 mechanical 
index.
Acoustic Activation of C3 versus C3C4 Droplet Infusions
A total of eight pigs were examined with both the C3 and C3C4 droplet infusions. During 
the C3 infusion, consistent myocardial opacification and left ventricular cavity contrast were 
seen in all eight pigs with the 1.3 MHz triggered (once every one and four cardiac cycles at 
end systole) harmonic imaging modality (Figure 3 example). No myocardial contrast and 
minimal left ventricular cavity contrast was seen with 1.7 MHz low MI power modulation 
imaging. However, in the six pigs in which real time high MI harmonic imaging at 1.7 MHz 
was tested, myocardial contrast enhancement was observed in the un-infarcted myocardial 
microcirculation with excellent delineation of perfusion defects in five of six animals 
(Figure 4; Videos 2). This contrast persisted during and for up to three minutes following 
cessation of the 20% C3 infusion, and a time lapse quantitative measurements of contrast 
disappearance from the cavity and myocardium indicated that there was a linear 
disappearance of contrast from both regions (Figure 5), indicating the created microbubbles 
were, for the most part, behaving as intravascular tracers and were not trapped within the 
microcirculation.
In the three pigs in which a triggered 1.7 MHz high MI end systolic image (1:1 triggering) 
was compared to a real time 1.7 MHz image at the same MI, there was a slight, but highly 
significant increase in myocardial contrast intensity was observed (p<0.00001; n = 18 
comparisons in the three pigs). This would indicate that simultaneous generation and 
destruction of microbubbles is occurring in the microcirculation while in the real time high 
MI mode (Figure 6).
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In none of the eight pigs was myocardial contrast achieved with the 20% C3C4 infusion.
Correlation with Infarct Size and Risk Area Assessments
At cardiac MRI, the average ejection fraction of the pigs was 45 ± 15% (range 29–74%). 
Median number of segments exhibiting transmural hyperenhancement was 4, with a range of 
1 to 6.
During the C3 infusion with triggered end systolic 1:1 imaging at 1.3 MHz, delineation of 
perfusion defects was possible. This was also possible with the real time high mechanical 
index 1.7 MHz harmonic imaging in five of six pigs tested. Under resting conditions before 
re-occlusion of the LAD, perfusion defect size (presumed infarct size) observed with 1:1 
triggering at high MI 1.3 harmonic imaging and 1.7 MHz real time high MI imaging 
averaged 1.86±1.29 cm2 while TTC measurements of infarct size were 1.90±1.31cm2. There 
was a close correlation between perfusion defect size and TTC measurements (r=0.95, 
p<0.001; Figure 7a) and with the number of transmurally infarcted segments measured at 
MRI (r=0.74, p=0.048). Figure 8 depicts two examples of infarctions detected with real time 
high MI imaging and corresponding TTC staining.
Assessment of perfusion defect size with the C3 infusion was possible during repeat LAD 
occlusion ischemia in seven pigs. In this setting, the average perfusion defect size with both 
1.3 MHz triggered and 1.7 MHz real time high MI imaging correlated closely with unstained 
areas on post mortem Evans Blue staining (r=0.97;p<0.001; Figure 7b).
Safety
During infusions of both agents, no changes in heart rate, systolic arterial pressure, or 
oxygen saturation were observed (Table). None of the animals exhibited premature 
ventricular contractions or other arrhythmias during the infusion of either C3 or C3C4. Post 
mortem TTC staining indicated no evidence of hemorrhage within the normal myocardium, 
or within the infarct zones.
DISCUSSION
This is the first paper to demonstrate that intravenous nanodroplets can be acoustically 
activated with conventional transthoracic phased array transducers to detect both infarct size 
and risk area. Although these droplets were acoustically undetectable with conventional low 
mechanical index techniques traditionally used to detect perfusion with microbubbles, they 
were consistently activated with triggered high mechanical index harmonic techniques, and 
more importantly visualized within the microcirculation with real time high mechanical 
index harmonic imaging techniques.
Following acoustic activation, the C3 nanodroplets behaved similar to what has been 
described with larger sized more concentrated intra-arterially injected microbubbles (5), in 
that they were resistant to high mechanical index ultrasound destruction. It is unlikely that 
these were microbubbles were trapped within the microcirculation, since their disappearance 
following infusion termination correlated with disappearance of left ventricular cavity 
contrast. The 600–650 nanometer sized droplets would be expected to result in microbubbles 
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that were at least 3–4 microns in size (7), and perhaps slightly larger due to inward diffusing 
dissolved nitrogen gas within the blood stream. Even at these sizes though, they would still 
be expected to pass freely through the myocardial capillaries (13) while also being more 
resistant to destruction than smaller sized perfluorocarbon microbubbles (14). Intravenously 
infused commercially available microbubbles within the capillaries would not be visualized 
at this high mechanical index and frame rate, since capillary blood replenishment with 
intravenously infused C3 microbubbles would not be expected at this frame speed (10). It is 
possible, therefore, that these created microbubbles were in a unique size range that was 
resistant to ultrasound induced destruction but still capable of acting as free intravascular 
tracers. Other explanations for their resistance to destruction may be their resistance to shell 
buckling in response to diagnostic ultrasound pressures. High speed optical imaging has 
shown that in some cases, microbubbles recently formed from vaporized liquid 
perfluorocarbons behave differently in response to diagnostic ultrasound when compared to 
commercially available microbubbles, and do not exhibit shell buckling (15). Whether this 
renders them more resistant to destruction is not clear. One important caveat from this is that 
these created microbubbles cannot be used for the perfusion imaging techniques that take 
advantage of microbubble destruction to quantify myocardial blood flow (3).
Also, we did not observe any evidence of leaking of the microbubbles into infarcted 
segments. This may have been due to our ability to only activate only the “larger” 600 
nanometer C3 droplets that were confined to the intravascular spaces. According to the 
characterization results, the nanodroplets were polydisperse. It has been shown that the 
droplet activation threshold increases with decreasing droplet diameter (6). Therefore, it is 
possible that that observed contrast enhancement was due to the activation of larger droplet 
content, and droplets small enough to cross damaged endothelial membranes may not have 
been activated at the pressures tested herein. This may explain the close correlation between 
contrast defect size with triggered high MI imaging and TTC measurements of infarct area 
as well as Evans Blue measurements of risk area.
C4 droplets, and droplets with 50% C4 content as used in the current study, appear to be 
more difficult to activate with the MI limits currently available with conventional diagnostic 
transthoracic transducers at the depths required for cardiac imaging in the pig and humans 
(approximately 4–10 centimeters from the anterior to posterior borders for transthoracic 
parasternal imaging as demonstrated in Figures 3–5). This is in agreement with in vitro 
studies that indicated that the droplet activation threshold increases with increasing 
molecular weight of the perfluorocarbon core (7).
Limitations of Nanodroplet Formulations
A problem with the technique used to create droplets in the current study was the 
polydisperse nature of the formed droplets, ranging from 100 to 700 nm in diameter. It is 
possible that more monodisperse droplet distributions, designed for different clinical 
applications, could be created through techniques such as microfluidic particle generation 
(16) or by optimizing the size distribution of the precursor bubble population.
The microbubbles created in this study were resistant to high MI destruction, and thus 
cannot be used to perform targeted myocardial blood flow calculations similar to what is 
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currently done with destruction replenishment curves using commercially available 
microbubbles (3). However, since the generated microbubbles still appear to function as free 
intravascular tracers, the targeted activation of left ventricular cavity droplets with a three 
dimensional high mechanical index impulse following a bolus intravenous injection could be 
utilized as an input function to generate myocardial contrast time intensity curves to 
quantitatively assess transit rates that correlate with myocardial blood flow (17). Further 
work is needed to assess the feasibility of such methods.
Clinical Implications/Future Directions
All infusions of the nanodroplets resulted in no changes in myocardial function across a 
wide range of ejection fractions, and no changes in hemodynamics, oxygen saturation, or 
damage outside the infarct zones. Therefore, this study suggests there is clinical potential for 
this technique for real time high mechanical index transthoracic perfusion imaging. 
Although C3 droplets have not been tested with transthoracic imaging in humans, these pigs 
were large animals (mean weight 64 ± 6 kg) and their parasternal locations for left 
ventricular cavity were similar to that which is seen in humans. The mechanical indices that 
were required to activate the microbubbles and permit myocardial contrast enhancement in 
both the near and far field were well within Food and Drug Administration limits.
This targeted activation technique at a high mechanical index may improve the dynamic 
range within which myocardial blood volume can be analyzed and quantified with contrast 
echocardiography. Additional studies are needed to determine whether more precise sizes of 
nanodroplets can be created that would allow a consistent size of microbubble to be 
produced. Activation of the smaller 100–200 nanometer droplets that cross defective 
endothelial borders into infarct zones may allow highlighting of the infarct zone in a manner 
currently seen with delayed enhancement imaging, but this still has not been demonstrated. 
Droplets of larger size like those activated in the current study may be used to better 
delineate myocardial contrast defects seen with infarction, as well as identify normal 
myocardial contrast enhancement within dysfunctional segments (i.e. hibernating 
myocardium). Overall, the ability intravenous droplets to bypass the lung filtering effect and 
permit targeted acoustic activation only to zones where myocardial contrast is needed may 
further improve the safety of ultrasound contrast imaging and allow higher quality imaging 
of myocardial blood volume in acute coronary syndromes.
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This study demonstrates the potential for transthoracic ultrasound to target both the 
activation and imaging of systemically administered acoustic droplets that are less than 
one micron in size. Consistent real time visualization of myocardial contrast 
enhancement was possible at 1.3 and 1.7 MHz frequencies. This targeted acoustic 
activation of intravenous perfluorocarbon droplets has not been previously demonstrated. 
Since these droplets range in size from 50 to 600 nanometers, and do not become 
microbubbles until acoustically activated, they could be used for prolonged periods of 
time following intravenous injection, and could be used to accurately identify the 
transmural extent and size of infarction in real time at a high mechanical index.
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The typical appearance of the C3 nanodroplets diluted to 15% in normal saline prior to 
infusion. Note the near complete absence of any microbubbles.
Porter et al. Page 12














An example of C3 droplet activation during a continuous infusion of the droplets as 
mechanical index is increased at the 1.3 MHz frequency. Image frame rate was 30 Hertz
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Triggered 1.3 MHz high MI imaging during a C3 nanodroplet infusion in a pig with a small 
previous small inferoseptal myocardial infarction (arrows).
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Real time high mechanical index imaging of microcirculatory microbubbles activated during 
real time 1.7 MHz transthoracic imaging during acute LAD ischemia. Frame rate is 64 Hz; 
MI is 1.3.
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Demonstration of the washout of the myocardial and left ventricular cavity contrast after the 
C3 has been injected using a 1:1 triggering imaging technique. Using Q Lab software, this 
intensity was plotted on the accompanying graph to demonstrate the corresponding 
disappearance of contrast as a function of time, verifying that the contrast in the 
myocardium is not coming from trapped microbubbles within the microcirculation.
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A representative image and graphical display of the myocardial contrast enhancement 
achieved at 1:1 triggering at end systole versus real time imaging at the same high 
mechanical index (1.2). The comparisons (n=19) were done in three separate pigs. There 
was a slight, but highly significant (p<0.0001), increase in signal intensity while in the 
triggering mode. This would indicate that some simultaneous generation and destruction of 
microbubbles is occurring in the microcirculation while in the real time high MI. *p<0.0001 
compared to real time imaging.
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Correlations between TTC derived infarct area (left panel) and averaged defect size from 1.3 
MHz/2.6 MHz transthoracic triggered imaging and 1.7/3.4 MHz real time harmonic imaging 
(r=0.95; p<0.001). During repeat left anterior descending occlusion, the Evans Blue (EB) 
unstained area correlated closely with perfusion defect size using either the triggered 1:1 
high MI setting or real time high MI setting. Data points are the same as pig number, and the 
correlations represent the average of measurements from the 1.3 MHz triggered data and 1.7 
MHz real time data for each pig.
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Representative examples of infarction (arrows) detected using the 1.7 MHz real time (Case 
1) and 1.3 MHz real time (Case 2) frequencies at a high mechanical index in real time. The 
accompanying TTC images are also displayed.
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Table














C3 infusion 68.0 68.1 98.5 94.1 85.8 89.6
C3/C4 infusion 69.3 71.8 97.8 96.4 82.4 85.5
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